The first ICI against CTLA-4 was named Ipilimumab, and got FDA approval for melanoma treatment in 2011 [36], while the first PD-L1 ICI against melanoma was Pembrolizumab and got FDA approval in 2014 [37]. The gene discussed is CD274; the disease is melanoma.